Abstract |
The purpose of the present study was to determine whether graded levels of low-flow ischemia would lead to graded differences in uptake and clearance of BMS181321. Using a perfused rat heart model, 7.4 MBq (200 microCi) of BMS181321 was infused over 20 min, followed by a 60-min clearance phase. Activity was monitored using an NaI detector. Four groups were studied using Krebs-Henseleit buffer perfusion using low flow or hypoxia: group 1=12 ml/min, group 2=3 ml/min, and group 3=1 ml/min during uptake and clearance phases, and group 4=12 ml/min with hypoxia during clearance. Control and low-flow groups were also perfused using red blood cells and albumin. There was a stepwise increase in peak myocardial uptake (% injected dose) as flow progressively decreased (group 1=2.4%+/-0.2% SEM, group 2=13.1%+/-0.7%, group 3=28.6%+/-2.4%, P <0.05). Group 3/group 1 mean peak activity ratio was 12:1. Mean 1-h fractional retention significantly increased in a stepwise manner as flow decreased (group 1=0.32+/-0.02, group 2=0.43+/-0.03, group 3=0.59+/-0.05, P <0.05). Group 3/group 1 mean 1-h clearance activity ratio was 30:1. Groups 5 and 6 perfused with red blood cells and albumin demonstrated similar increases in peak uptake and 1-h retention in the low-flow hearts. This study demonstrates a stepwise increase in uptake and a stepwise increase in retention rate of BMS181321 with progressive reduction in flow.
|
Authors | R D Okada, K N Nguyen, H W Strauss, G Johnson 3rd |
Journal | European journal of nuclear medicine
(Eur J Nucl Med)
Vol. 23
Issue 4
Pg. 443-7
(Apr 1996)
ISSN: 0340-6997 [Print] Germany |
PMID | 8612666
(Publication Type: Journal Article)
|
Chemical References |
- Nitroimidazoles
- Organotechnetium Compounds
- BMS 181321
- Technetium
|
Topics |
- Animals
- Hypoxia
(physiopathology)
- Myocardial Ischemia
(metabolism)
- Myocardium
(metabolism)
- Nitroimidazoles
(pharmacokinetics)
- Organotechnetium Compounds
(pharmacokinetics)
- Rats
- Technetium
- Time Factors
|